Pharmaceutical company Boehringer Ingelheim announced on Wednesday the availability of the new Quarterable Snap-Tab design for PREVICOX (firocoxib) Chewable Tablets for dogs, following approval from the US Food and Drug Administration (FDA).
The new tablet design is double scored to enable easier division of the tablet into quarters, assisting with customisable dosing for a broader range of dogs based on weight. The new scoring design helps veterinarians to prescribe lower dosages for dogs as small as seven pounds, and more dosage options using the new quarterable 57 mg and 227 mg chewable tablets.
PREVICOX (firocoxib), a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), is approved for the control of pain and inflammation related with osteoarthritis in dogs, and for the control of postoperative pain and inflammation associated with soft-tissue and orthopaedic surgery.
Johnson & Johnson reveals new Phase 2 nipocalimab study data in Sjögren's disease
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
Agilent acquires Proscia for USD240m
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
StimLabs launches DermaForm collagen scaffold particulate device
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Roche wins FDA clearance for customisable respiratory pathogen test
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Immunome secures EMA validation of varegacestat application for desmoid tumors